Table 1.
Baseline Characteristics of Selected Studies Included in the Meta‐Analysis
| Author | Country, Year | Procedure | Type of Valve | Sample Size, n | Study Design | Male (%) | Age, y (Mean) | Mean STS Score (%) | RV Measurement (TAPSE, FAC, or S′) | Degree of TR | Pulmonary HTN | Duration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRV RVD | NRV RVD | NRV RVD | NRV RVD | NRV RVD | NRV RVD | |||||||
| 1. Ito et al15 | USA, 2013 | TF‐TAVR, TA‐TAVR | Sapiens XT | 268 | Prospective |
50 72.1 |
80.5±8.1 80.1±7.6 |
9.5±4.8 10.8±5.6 |
No RV dilation: 200 | TR in no RV dilation: 21 | PASP in no RV dilation: 41.5±11.8 | 5 y |
| RV dilation: 68 | TR in RV dilation: 31 | PASP in RV dilation: 55.2±17.3 | ||||||||||
| 2. Koifman et al16 | USA, 2015 | TAVR | CoreValve | 606 | Prospective |
42 65 |
84±7 81±9 |
9.1±4.4 9.5±5.3 |
FAC >0.35: 146 | TR in no RV dilation, 19 | PASP in RVSD: 50±17 | 1 y |
| FAC <0.35: 460 | TR in no RV dilation: 38 | PASP in no RVSD: 44±16 | ||||||||||
| 3. Lindman et al20 | USA, 2012 | TAVR (from PARTNER II trial) | Sapiens, Sapiens XT | 488 | RCT |
49 56 |
84±8 86±10 |
10.1±5.3 11.5±6.0 |
Normal S′ :68 | No TR/mild TR: 372 | PASP for mild MR: 27; moderate: 31 | 1 y |
| Abnormal S′: 50 | Moderate TR: 117; severe TR: 18 | Severe: 28 | ||||||||||
| 4. Poliocikovaet al23 | UK, 2011 | TF‐TAVR, TA‐AVR, TS‐TAVR | Medtronic | 142 | Prospective |
61 48 |
79±4.7 82±6.3 |
Not reported | TAPSE <15: 18 | Mild TR: 97 (62.6%); moderate TR: 20 (12.9%) | Mean PAP for mild TR: 45 (29.0%) | 4 y |
| TAPSE >15: 124 | Severe TR: 13 (8.4%) | Moderate TR: 15 (9.7%); severe TR: 14 (9%) | ||||||||||
| 5. Schwartz et al14 | Israel, 2009 | TAVR | Not reported | 519 | Prospective |
43 46 |
82.4±6 84.8±5 |
Euroscore: 22.2±14 27.9±13 |
TAPSE in mild TR: 19.5±4 |
TR < moderate: normal, 37; mild: 46; moderate: 16; severe: 7 |
PASP in TR < moderate: 39.4±13 | 3 y |
|
TAPSE in moderate/severe TR: 18.4±5 |
TR > moderate: normal, 5; mild, 46; moderate, 47; severe, 12 |
PASP in TR > moderate: 61.2±13 | ||||||||||
| 6. Griese et al13 | Germany, 2014 | TF‐TAVR, TA‐TAVR | Sapiens XT, CoreValve | 702 | Prospective |
39.3 60 |
80±2 82±5 |
Euroscore: 30±15 17.±12 |
TAPSE >18: 462 | Not reported | Not reported | 5 y |
|
TAPSE 14–18: 190; TAPSE <14: 50 |
||||||||||||
| 7. Hutter et al5 | Germany, 2014 | TF‐TAVR, TA‐TAVR | Sapiens, CoreValve | 251 | Prospective |
47.9 45.5 |
80.8±6.4 80.5±7.4 |
5.7±3.4 7.1±4.3 |
Normal RV: 161 | Reported with MR | Mean PAP >60 mm Hg: 62 | 1 y |
| RV dysfunction: 45 | Mean PAP >60 mm Hg: 206 | |||||||||||
| 8. Lindsay et al21 | UK, 2016 | TF‐TAVR | Sapiens | 190 | Prospective |
49 51 |
79.7 81.4 |
Not reported |
Cardiac MRI RVEF >50: 145 |
Not reported | PASP RV <50 mm Hg: 45 | 2 y |
|
Cardiac MRI RVEF <50: 45 |
HTN indicates hypertension; MR, mitral regurgitation; MRI, magnetic resonance imaging; NRV, normal right ventricular function; PAP, pulmonary artery pressure; PASP (mm Hg), pulmonary artery systolic pressure (mm Hg); RVD, right ventricular dilation; RVEF, right ventricular ejection fraction; RVSP, right ventricle systolic pressure; S′, tricuspid lateral annular systolic velocity; STS, Society of Thoracic Surgeons operative mortality risk score; TA‐TAVR, transapical transcatheter aortic valve replacement; TF‐TAVR, transfemoral transcatheter aortic valve replacement; TR, tricuspid regurgitation; and TS‐TAVR, transseptal transcatheter aortic valve replacement.